drugset / Trial / NCT02580331

1% Metformin Gel in the Treatment of Class II Furcation Defects

NCT02580331

RandomizedParallel-groupDouble-blindTreatment

Summary

Metformin (MF), a biguanide group of anti-diabetic drug has been shown to enhance osteoblasts differentiation and inhibit osteoclast differentiation in vitro, thus may exhibit a favourable effect on alveolar bone. The present study aims to explore the efficacy of 1% MF gel as a local drug delivery system in adjunct to scaling and root planing (SRP) for the treatment of Class II furcation defects in comparison with placebo gel.

Timeline

Start
2014-11
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 1 % Other

Indications